Recommendation of the President – Ayvakyt (avapritinib)
On 5 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 82/2024 on the evaluation of the drug Ayvakyt (avapritinib) under the drug program “Treatment of patients with advanced forms of systemic mastocytosis (ICD-10: C96.2, C94.3, D47.9)”